Ryvu Therapeutics S.A.
RVU.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | PLN 1 | PLN 1 | PLN 1 | PLN 1 |
| - Cash | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| + Debt | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Enterprise Value | PLN 1 | PLN 1 | PLN 1 | PLN 1 |
| Revenue | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| % Growth | 20.3% | -26.8% | -33.7% | – |
| Gross Profit | -PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| % Margin | -191.4% | 72.8% | 78.1% | 77.1% |
| EBITDA | -PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |
| % Margin | -132.7% | -228.8% | -125.1% | -120.1% |
| Net Income | -PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |
| % Margin | -165.6% | -271.4% | -149.3% | -137.2% |
| EPS Diluted | -1.1 | -1.5 | -1.1 | -1.52 |
| % Growth | 26.7% | -36.4% | 27.6% | – |
| Operating Cash Flow | -PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |
| Capital Expenditures | -PLN 0 | -PLN 0 | -PLN 0 | PLN 0 |
| Free Cash Flow | -PLN 0 | -PLN 0 | -PLN 0 | -PLN 0 |